Viz.ai
AI triage platform that alerts stroke specialists within seconds of a scan completing.
About
Viz.ai sits in the radiology pipeline and analyzes imaging in real time, looking for large vessel occlusion, intracranial hemorrhage, aneurysm, pulmonary embolism, and other time-critical findings. When it finds something, it pushes an alert straight to the specialist's phone. The company's Contact application was the first AI stroke-detection software cleared by the FDA, and the platform now carries 50+ FDA-cleared algorithms across 2,000+ US hospitals covering a reported 230 million lives, with 70,000+ clinician users. The company hit profitability in its core healthcare business in 2025 at a $1.2 billion valuation.
Two caveats worth stating. The DUEL study presented at the 2025 International Stroke Conference found RapidAI identified 98% of large vessel occlusions versus 74% for Viz LVO, a meaningful performance gap on that specific task. And Viz.ai's revenue remains heavily concentrated in stroke, so hospitals are betting on a still-narrowing platform as it pushes into cardiology and other specialties.
What it can do
- Real-time large vessel occlusion detection
- Intracranial hemorrhage detection and volumetry (Viz ICH Plus)
- Mobile alerts to specialists within seconds of scan
- Multi-specialty care coordination workflows
- 50+ FDA-cleared algorithms across neuro, cardio, and trauma
Setup
Hospitals integrate Viz.ai with their PACS/radiology pipeline through an enterprise deployment. Imaging studies route through the AI automatically; alerts go to specialists' mobile devices via the Viz app. Care coordination workflows are configured per service line (stroke, cardiology, trauma).
Prerequisites
Enterprise contract; PACS integration; CT/CTA imaging capability; specialists enrolled for mobile alerts.
Use cases
Works with
Trust score — 8/10
Scored 8/10 (verified tier, metrics-v1). Evidence: First FDA-cleared AI stroke-detection software (Viz.AI Contact); 50+ FDA-cleared algorithms now; 2,000+ hospitals, 70,000+ clinicians, reported 230M lives covered; profitable 2025, $1.2B valuation; Honest caveat: DUEL study (ISC 2025) showed RapidAI identified 98% of LVOs vs 74% for Viz LVO; Revenue concentration in stroke flagged as platform risk.
Sources
Every fact above was checked against these sources. Where a claim comes from the provider and couldn't be independently verified, the text says so.